Compare Charles River Laboratories Intl. Inc (CRL) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Pfizer Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $282 (market cap $13.46B), while Pfizer Inc trades at $26.46 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 11.3× Charles River Laboratories Intl. Inc's market cap, and Pfizer Inc pays a 6.46% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | PFE | |
|---|---|---|
Market Cap | $13.46B | $151.73B |
Sector | Health | Health |
52-Week High | $282.00 | $28.56 |
52-Week Low | $145.57 | $23.60 |
Enterprise Value | $16.30B | $203.22B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
